Lupus trials recruiting in Pennsylvania

All Lupus trials nationally

Cities in Pennsylvania

Recruiting trials in Pennsylvania

• A Phase 1 Study of FT819 in B-cell Mediated Autoimmune Disease
  NCT06308978 · Phase: Phase 1 · Ages: 12 Years to 70 Years · Sex: All (male and female) · Pennsylvania: Philadelphia
• A Phase IIa Study of ICG318 CAR-T in Refractory Systemic Lupus Erythematosus With or Without Lupus Nephritis
  NCT07328581 · Phase: Phase 2 · Ages: 16 Years to 70 Years · Sex: All (male and female) · Pennsylvania: Philadelphia
• A Study Describing the Efficacy and Safety of Belimumab Administered in Adult Participants With Early Systemic Lupus Erythematosus (SLE)
  NCT06411249 · Phase: Phase 4 · Ages: 18 Years and older · Sex: All (male and female) · Pennsylvania: Duncansville, Philadelphia
• A Study in Participants With Active Systemic Lupus Erythematosus With Inadequate Response to Glucocorticoids and ≥2 Immunosuppressants
  NCT07175285 · Phase: Not specified · Ages: 16 Years and older · Sex: All (male and female) · Pennsylvania: Philadelphia
• A Study of Nipocalimab in Adults With Moderate to Severe Systemic Lupus Erythematosus
  NCT07438496 · Phase: Phase 3 · Ages: 18 Years to 75 Years · Sex: All (male and female) · Pennsylvania: Philadelphia
• A Study of Quinacrine in Participants With Cutaneous Lupus Erythematosus
  NCT07694336 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · Pennsylvania: Philadelphia
• A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus
  NCT06617325 · Phase: Phase 3 · Ages: 16 Years and older · Sex: All (male and female) · Pennsylvania: Pittsburgh
• A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Obinutuzumab in Adolescents With Active Class III or IV Lupus Nephritis and the Safety and PK of Obinutuzumab in Pediatric Participants
  NCT05039619 · Phase: Phase 2 · Ages: 5 Years to 17 Years · Sex: All (male and female) · Pennsylvania: Philadelphia
• A Study to Test Whether Different Doses of BI 3000202 Help People With Systemic Lupus Erythematosus (SLE)
  NCT07409181 · Phase: Phase 2 · Ages: 18 Years to 74 Years · Sex: All (male and female) · Pennsylvania: Duncansville
• An Efficacy and Safety Study of Intravenous Anifrolumab to Treat Systemic Lupus Erythematosus in Pediatric Participants
  NCT05835310 · Phase: Phase 3 · Ages: 5 Years to 17 Years · Sex: All (male and female) · Pennsylvania: Philadelphia
• Autologous Stem Cell Transplant (ASCT) for Autoimmune Diseases
  NCT05029336 · Phase: Phase 2 · Ages: 8 Years to 25 Years · Sex: All (male and female) · Pennsylvania: Philadelphia
• CD19-Directed Chimeric Antigen Receptor Autologous T Cells (CART19) for Lupus
  NCT06839976 · Phase: Phase 1, Phase 2 · Ages: 12 Years to 29 Years · Sex: All (male and female) · Pennsylvania: Philadelphia
• Comparative Effectiveness of Online 8-session CBT vs. 1-Session Empowered Relief for Chronic Pain - The PROGRESS Study
  NCT05612750 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: All (male and female) · Pennsylvania: Allentown
• Effects of Stopping Hydroxychloroquine in Elderly Lupus Disease
  NCT05799378 · Phase: Phase 3 · Ages: 55 Years and older · Sex: All (male and female) · Pennsylvania: Hershey
• PRESERVE: LUPKYNIS in Combination With Belimumab, Obinutuzumab or Anifrolumab in Patients With Lupus Nephritis
  NCT07611214 · Phase: Phase 4 · Ages: 18 Years to 75 Years · Sex: All (male and female) · Pennsylvania: Willow Grove
• Prevalence and Clinical Severity of Cutaneous Lupus Erythematosus
  NCT01510067 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female) · Pennsylvania: Philadelphia
• RESET-SLE: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Systemic Lupus Erythematosus
  NCT06121297 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 65 Years · Sex: All (male and female) · Pennsylvania: Philadelphia
• Study of Efficacy and Safety of LNP023 in Participants With Active Lupus Nephritis Class III-IV, +/- V
  NCT05268289 · Phase: Phase 2 · Ages: 18 Years to 100 Years · Sex: All (male and female) · Pennsylvania: Philadelphia, Pittsburgh
• Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO
  NCT03816345 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · Pennsylvania: Philadelphia, Pittsburgh
• VIBRANT: VIB4920 for Active Lupus Nephritis
  NCT05201469 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · Pennsylvania: Hershey, Philadelphia